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https://doi.org/10.1016/j.stemcr.2020.06.021Characterized by the expansion of somatic mutations in the he-
matopoietic lineages of aging individuals, clonal hematopoiesis
of indeterminate potential (CHIP) is a common condition that in-
creases the risk of developing hematological malignancies and car-
diovascular disease (CVD). The presence of CHIP-associated muta-
tions in hematopoietic stem and progenitor cells (HSPCs) suggests
that these mutations may alter the functions of the diverse he-
matopoietic lineages, many of which influence the pathogenesis
of CVD. Inflammationmay be a potential pathogenicmechanism,
linking both CVD and hematological malignancy. However, it re-
mains unknown whether CHIP-associated CVD and hematologi-
cal malignancy are features of a common disease spectrum. The
contributions of CHIP-associated mutations to both CVD and he-
matological malignancy underscore the importance of stem cell
biology in pathogenesis and treatment. This review discusses
possible mechanisms underlying the contributions of multiple he-
matopoietic lineages to CHIP-associated CVD and the putative
pathogenic links between CHIP-associated CVD and hematologi-
cal malignancy.Introduction
With age, individuals acquire somatic mutations in their
hematopoietic stem and progenitor cells (HSPCs), which
produce the various blood cell lineages, including mono-
cytes, mast cells, neutrophils, megakaryocytes, B cells,
and T cells (Jaiswal and Ebert, 2019). Some of these muta-
tions can promote the competitive advantage and expan-
sion of specific leukocyte clones in a process called clonal
hematopoiesis (CH) (Jaiswal and Ebert, 2019). The presence
of CH in the context of aging is called age-related clonal he-
matopoiesis (ARCH), which describes the existence of any
stem cell subpopulation or clone (Busque et al., 2018).
When these clones harbor mutations in preleukemic genes
at a variant allele frequency (VAF) of 2% or greater, they
define a novel condition called clonal hematopoiesis of
indeterminate potential (CHIP), in which seemingly
healthy individuals are at an increased risk of developing
hematological disease (Jaiswal et al., 2014). Depending on
the depth of DNA sequencing, CHIP can be detected in as
high as 95% of adults, making it a very common but poorly
understood phenomenon (Young et al., 2016). Epigenetic
regulators, including the Tet methylcytosine dioxygenase 2
(TET2), DNA methyltransferase 3A (DNMT3A), and associ-292 Stem Cell Reports j Vol. 15 j 292–306 j August 11, 2020 j ª 2020 The A
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in CHIP (Jaiswal and Ebert, 2019). In leukemia, mutations
in these genes are often present inHSPCs early in the devel-
opment of hematological malignancy (Jan et al., 2012).
However, the scope of the pathogenesis and the clinical im-
plications of CHIP have not yet been fully characterized.
Remarkably, recent studies have also linked CHIP to an
increased risk of cardiovascular and cerebrovascular dis-
ease (CVD), including atherosclerosis, myocardial infarc-
tion, and ischemic stroke (Jaiswal et al., 2014, 2017).
This correlation suggests that preleukemic mutations in
hematopoietic lineages can predispose individuals to
CVD and that CVDmay be an important clinical manifes-
tation of CHIP. Recently, CHIP has been linked to inferior
outcomes in heart failure patients (Dorsheimer et al.,
2019). The magnitude of the VAF correlated with the
severity of the clinical outcome, suggesting an important
role for the expansion of clones containing CHIP-associ-
ated mutations in CVD pathogenesis (Dorsheimer et al.,
2019). The effects of CHIP-associated mutations on
atherosclerosis and heart failure, but not cerebrovascular
disease, have been confirmed in mouse models. Trans-
plantation of Tet2-deficient bone marrow (BM) into the
Low-density lipoprotein receptor (Ldlr)-deficient mouse
model of atherosclerosis susceptibility accelerated athero-
sclerosis via pro-inflammatory macrophages (Fuster et al.,
2017; Jaiswal et al., 2017). Similarly, mice transplanted
with Tet2-deficient BM exhibited worse cardiac remodel-
ing in heart failure models (Sano et al., 2018a, 2018b).
Expression of mutant Janus kinase 2 (JAK2), which is also
mutated in CHIP, in myeloid cells exacerbated heart fail-
ure by promoting inflammation and cardiac remodeling
(Sano et al., 2019). Notably, transplant of Tet2-deficient
BM into non-irradiated wild-type mice increased fibrosis
and hypertrophy, indicating that loss of Tet2 in BM may
not only exacerbate existing CVD but may also directly
cause CVD (Wang et al., 2020).
CHIP also affects the outcomes of cardiac procedures,
implicating it inmultiplemanifestations of CVD. The pres-
ence of CHIP-associatedmutations increased all-causemor-
tality after transcatheter aortic valve implantation (Mas-
Peiro et al., 2020). Remarkably, CVD is also observed inuthor(s).
ecommons.org/licenses/by-nc-nd/4.0/).
Figure 1. Putative Contributions of He-
matopoietic Lineages to CVD and Poten-
tial Links between CHIP-Associated CVD
and Hematological Diseases
HSPCs give rise to the many hematopoietic
cell lineages. CHIP mutations (yellow star)
in HSPCs are transmitted to mature he-
matopoietic lineages, many of which play
roles in the different stages of CVD by
modulating the inflammatory response. The
roles of CHIP-associated mutations in these
different cell types have not yet been
explored. CHIP-associated mutations have
been linked to both CVD and hematological
malignancy, but it is not yet known if these
two pathologies represent a common dis-
ease process or distinct events. LT-HSPCs,
long-term HSPCs; ST-HSPCs, short-term
HSPCs; CLPs, common lymphoid pro-
genitors; CMPs, common myeloid pro-
genitors; MC, mesenchymal cell; EC, endo-
thelial cell.
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tion (HSCT). Similar to CHIP patients, HSCT patients
exhibit coronary heart disease and heart failure (Armenian
andChow, 2014; Armenian et al., 2012). Notably, HSCT pa-
tients developing CVD tended to be older, and condition-
ing regimens included total body irradiation, chest irradia-
tion, and anthracycline treatment (Armenian et al., 2018).
It is not yet known if CVD in HSCT patients can be attrib-
uted to CHIP-associatedmutations. However, if so, it would
suggest that HSPCs carrying CHIP-associated mutations
have intrinsic pathogenic features that enable them to pro-
mote CVD in a new environment. HSPCs bearing CHIP-
associated mutations can preserve cell-autonomous fea-
tures under stressful conditions, such as transplantation,
but additional studies are needed to investigate this possi-
bility in the context of CVD (Yu et al., 2016).
Collectively, these studies support a broad role for CHIP-
associated mutations in CVD, affecting multiple stages in
its pathogenesis. They indicate that CHIP is an importantnovel risk factor for CVD in seemingly healthy individuals,
but much remains unknown regarding the mechanisms
underlying its contributions toCVD. The breadth of CHIP’s
effects is consistent with the diverse functions of the he-
matopoietic cell types,many ofwhich play significant roles
in CVD (Swirski and Nahrendorf, 2018). The presence of
CHIP-associated mutations in HSPCs suggests that these
mutations have the potential to influence multiple cell
types involved in CVD as well as cause hematological ma-
lignancy, providing a possible link between these pathol-
ogies (Figure 1). However, these processes are only begin-
ning to be explored. It is not yet known if mutant HSPCs
or their differentiated progeny contribute to or cause
CHIP-associated CVD. Two important unanswered ques-
tions regarding CHIP are (1) whether CHIP-associated mu-
tations alter the functions of multiple hematopoietic
lineages and (2) whether CHIP-associated CVD and hema-
tological malignancies represent a common disease pro-
cess. The objective of this review is to discuss support forStem Cell Reports j Vol. 15 j 292–306 j August 11, 2020 293
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investigation.
CVD Is a Complex Process Involving Multiple Cell
Types and Stages
CVD is a dynamic process involving multiple stages (Libby
et al., 2019a; Libby and Kobold, 2019). Atherosclerosis is
characterized by the accumulation of lipid plaques in ves-
sels, and its progression increases the risk for myocardial
infarction, which can cause heart failure (Swirski and Nah-
rendorf, 2013). Importantly, many types of leukocytes play
key and distinct roles throughout CVD (Swirski and Nah-
rendorf 2013, 2018). During the stages of CVD, these cell
types interact to promote either inflammation or repair (Ta-
bas and Lichtman, 2017; Tourki and Halade, 2017). The
most abundant leukocytes in atherosclerotic lesions, mac-
rophages are involved in both the promotion and regres-
sion of inflammation (Swirski andNahrendorf, 2013). Neu-
trophils modulate monocyte recruitment and oxidative
stress, while platelets facilitate monocyte entry into pla-
ques and promote thrombus formation (Swirski and Nah-
rendorf, 2013). B cells and T cells can either promote or
inhibit atherosclerosis (Swirski and Nahrendorf, 2013). In
heart failure, B cells influence the myocardial leukocyte
pool and affect myocardial mass and left ventricular
contractility (Adamo et al., 2020). CD8+ T cells attenuate
inflammation and promote scar formation, and their loss
increases the numbers of neutrophils and macrophages,
indicating cooperation among hematopoietic lineages in
CVD (Ilatovskaya et al., 2019). Mast cells destabilize pla-
ques, attract monocytes and neutrophils from the BM to
the injured heart, and affect fibrosis (Lagraauw et al.,
2019; Legere et al., 2019; Swirski and Nahrendorf, 2018).
Neutrophils also aid in macrophage polarization into
distinct subtypes, highlighting the complex contributions
of different hematopoietic cell subtypes to CVD (Swirski
and Nahrendorf, 2018). The involvement of multiple he-
matopoietic lineages throughout the various stages of
CVD provides many opportunities for CHIP to influence
CVD; however, the roles of these cell types in the context
of CHIP are only beginning to be investigated.
Inflammation May Be a Key Mechanism for CHIP-
Associated CVD
Many of the hematopoietic lineages contribute to the in-
flammatory response, and recent studies suggest that
inflammation may play a critical role in the pathogenesis
of CHIP-associated CVD (Fuster et al., 2017; Sano et al.,
2018a, 2018b; Wang et al., 2020). The accelerated athero-
sclerosis observed in Ldlr-deficient mice transplanted with
Tet2-deficient BM is attributed to pro-inflammatorymacro-
phages secreting increased interleukin-1b (IL-1b) via NOD-,
LRR-, and pyrin domain-containing protein 3 (NLRP3), a294 Stem Cell Reports j Vol. 15 j 292–306 j August 11, 2020key inflammatorymediator that cleaves IL-1b into its active
form (Fuster et al., 2017). TET2 regulates the expression of
NLRP3 and IL-1b as well as NLPR3-mediated cleavage of IL-
1b; consequently, Tet2 inactivation increases IL-1b levels
(Fuster et al., 2017). Elevated expression of CXCmotif che-
mokine ligand (Cxcl) 1, Cxcl2, Cxcl3, platelet factor 4 (Pf4),
and IL-6 was also observed, indicating that the inflamma-
tory response in CHIP-associated CVD may be complex
(Jaiswal et al., 2017). In heart failure, loss of Tet2 prevented
recovery and promoted inflammation, indicating that
inflammation may contribute to CHIP-associated CVD in
different disease contexts and stages (Sano et al., 2018a,
2018b). Inhibition of the NLRP3 inflammasome reduced
fibrosis and hypertrophy and normalized cardiac func-
tions, suggesting that macrophages play a similar role in
both atherosclerosis and heart failure in mice (Sano et al,
2018b). These results are consistent with previous studies
showing that TET2 prevents the expression of inflamma-
tory genes and that tumor necrosis factor alpha (TNF-a)
promotes the expansion of Tet2-deficient HSPCs in vitro
(Cull et al., 2017; Abegunde et al., 2018). Similarly, inacti-
vation of Dnmt3a in mice promotes mast cell activation,
supporting the notion that inflammation may be a key
mechanism underlying CHIP-associated CVD (Leoni
et al., 2017). In a model of CHIP-associated CVD in which
mice transplanted with Tet2- or Dnmt3a-deficient BM cells
were stimulated with angiotensin II, loss of either Tet2 or
Dnmt3a caused cardiac and renal dysfunction, but differ-
ences in CVD kinetics and cytokine and chemokine expres-
sion were detected (Sano et al., 2018a). As the inflamma-
tory response in CVD involves a balance of resolving and
non-resolving factors, the increased inflammation due to
CHIP may impede the ability to effectively resolve inflam-
mation, leading to an exacerbation of CVD (Tourki and Ha-
lade, 2017). Notably, inflammation plays a differential role
in subtypes of heart failure (Schiattarella et al., 2020).
Consequently, CHIP may have distinct implications for
different types of heart failure.
As Tet2 loss promotes a pro-inflammatory macrophage
phenotype, it is possible that specific subpopulations of
macrophages exacerbate CHIP-associated CVD. Macro-
phages consist of diverse subpopulations and exhibit
distinct functions during the different stages of CVD path-
ogenesis and progression (Bajpai et al., 2018; Peled and
Fisher, 2014). These changes in cell-type subpopulations
and the stage of pathogenesismayhave significant implica-
tions for signaling. For example, while inhibition of IL-1b
reduces atherosclerotic plaque size, it is protective at later
stages of atherosclerosis (Gomez et al., 2018).While IL-1 re-
ceptor signaling appears to be important for CHIP-associ-
ated atherosclerosis in mice, it remains unclear whether
CHIP-associated CVD is exclusively IL-1-dependent or
whether additional inflammatory pathways contribute.
Table 1. Significant Studies Investigating CHIP-Associated CVD
Study Hematopoietic Cell Types Key Findings
Jaiswal et al. (2014) N/A Increased risks of hematologic cancer, all-cause mortality, coronary heart disease, and
ischemic stroke were observed in individuals with CHIP. Mutations in DNMT3A, TET2,
and ASXL1 constituted most of the CHIP variants in this study.
Montagner et al. (2016) Mast cells TET2 regulated mast cell differentiation. Upon IgE and antigen stimulation, Tet2-deficient
mast cells produced reduced levels of the mast cell cytokines IL-6, TNF-a, and IL-13.
Cull et al. (2017) Macrophages TET2 prevented inflammation and was highly expressed during macrophage differentiation.
Tet2 loss led to increased Il-1b, Il-6, and Arginase 1 during later stages of LPS stimulation
of BM-derived macrophages.
Fuster et al. (2017) Macrophages In Ldlr-deficient mice transplanted with Tet2-deficient BM cells, pro-inflammatory Tet2-
deficient macrophages increased the secretion of IL-1b via the NLRP3 inflammasome. TET2
regulated expression of the NLRP3. inflammasome. Inhibition of the NLRP3 inflammasome
impaired the growth of atherosclerotic plaques.
Jaiswal et al. (2017) N/A Increased risks of coronary heart disease, coronary-artery calcification, and early-onset
myocardial infarction were observed in individuals with CHIP. Ldlr-deficient mice
transplanted with BM from Tet2-deficient mice exhibited accelerated atherosclerosis.
Increased RNA and protein expression of IL-1b, IL-6, CXCL1, CXCL2, CXCL3, and PF-4 was
measured in these transplanted mice. Increased expression of IL-8 was detected in the
plasma of individuals with CHIP.
Leoni et al. (2017) Mast cells DNMT3A attenuated mast cell responses to acute and chronic stimuli. Loss of Dnmt3a was
associated with increased sensitivity to stimuli, increased cytokine release, and enhanced
degranulation capacity.
Abegunde et al. (2018) HSPCs Chronic TNF-a exposure promoted a clonogenic advantage for murine Tet2-deficient and
human TET2-mutant HSPCs in vitro. The expansion of these HSPCs coincided with resistance
to apoptosis and myeloid skewing. This study suggests an important role for HSPCs carrying
CHIP-associated mutations, in addition to mature hematopoietic lineages.
Buscarlet et al. (2018) N/A Patients with CHIP-associated mutations in TET2 or DNMT3A exhibited different
hematopoietic lineages. TET2 mutations correlated with greater myeloid populations and
no multipotent lineages, whereas DNMT3A mutations coincided with multipotent lineages.
The kinetics of clonal expansion differed with distinct CHIP-associated mutations.
Cai et al. (2018) HSPCs and myeloid cells Increased Tet2-deficient mature myeloid cells and HSPCs were detected in response to
inflammatory stress, leading to enhanced production of inflammatory cytokines, such as IL-
6. The long non-coding RNA Morrbid was increased in response to IL-6. Inhibition of SHP2
or STAT3 or loss of Morrbid inhibited CH of Tet2-deficient HSPCs.
Sano et al. (2018a) Macrophages In response to angiotensin II, mice lacking either Tet2 or Dnmt3a developed cardiac
hypertrophy, cardiac and renal fibrosis, and reduced cardiac function. The kinetics of clonal
expansion differed in Tet2- and Dnmt3a-deficient mice. Increased expression of Il-1b, Il-6,
and Ccl5 was detected in an LPS-stimulated Tet2-deficient macrophage cell line, whereas
elevation of Cxcl1, Cxcl2, Il-6, and Ccl5 was observed in an LPS-stimulated Dnmt3a-
deficient macrophage cell line.
Sano et al. (2018b) Macrophages Tet2-deficient hematopoietic or myeloid cells exacerbated cardiac remodeling and function
and correlated with increased IL-1b expression in transaortic constriction and chronic
ischemia models of heart failure. Inhibition of the NLRP3 inflammasome improved cardiac
measurements and alleviated heart failure development.
Wolach et al. (2018) Neutrophils CH for JAK2V617F, the most common driver of myeloproliferative neoplasm, correlated with
an increased occurrence of thrombosis. Mice expressing JAK2V617F exhibited increased NET
formation and thrombosis, which were alleviated by the JAK2 inhibitor ruxolitinib.
Cook et al. (2019) N/A Elevated expression of IL-6, MCP1/CCL2, and TNF-a was detected in individuals with CHIP.
Dorsheimer et al. (2019) N/A Patients with CHIP often had a history of hypertension. Mutations in TET2 or DNMT3A were
associated with worse heart failure outcomes.
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Study Hematopoietic Cell Types Key Findings
Mudersbach et al. (2019) N/A In response to TNF-a stimulation of endothelial cells, increased methylation was detected
at sites in the ACE promoter in a DNMT3A- and DNMT3B-dependent manner.
Sano et al. (2019) Myeloid cells Mice with myeloid expression of the JAK2V617F mutation demonstrated increased cardiac
inflammation and dysfunction after permanent left anterior descending artery ligation and
transverse aortic constriction.
Bick et al. (2020) N/A Individuals with large CHIP clones (VAF > 10%) that also carry an IL-6 receptor p.Asp358Ala
mutation exhibited fewer CVD events.
Mas-Peiro et al. (2020) T cells and myeloid cells Patients with aortic valve stenosis undergoing transcatheter aortic valve implantation and
carrying TET2 or DNMT3A mutations experienced worse outcomes. Patients with TET2
mutations showed increased pro-inflammatory non-classical monocytes, whereas patients
with DNMT3A mutations exhibited pro-inflammatory T cell polarization.
Veninga et al. (2020) Platelets Mutations in different CHIP-associated genes were linked to differences in platelet number
and risk of thrombosis and bleeding.
Wang et al. (2020) Myeloid cells Transplantation of Tet2-deficient BM cells into non-irradiated recipient mice resulted in
cardiac dysfunction, hypertrophy, and fibrosis. Macrophages isolated from the heart
exhibited upregulation of cytokines, cytokine receptors, and interferon-related genes and
downregulation of genes involved in regulation of cell differentiation and neurogenesis.
ACE, angiotensin-converting enzyme; ASXL1, Associated sex combs-like 1; BM, bone marrow; CHIP, clonal hematopoiesis of indeterminate potential; CCL2, C-
C motif chemokine ligand 2; Ccl5, C-C motif chemokine ligand 5; CXCL1, CXC motif chemokine ligand 1; CXCL2, CXC motif chemokine ligand 2; CXCL3, CXC motif
chemokine ligand 3; DNMT3A, DNA methyltransferase 3a; DNMT3B, DNA methyltransferase 3b; HSPCs, hematopoietic stem and progenitor cells; IgE, immu-
noglobulin E; IL-1b, interleukin-1b; IL-6, interleukin-6; IL-8, interleukin-8; IL-13, interleukin-13; JAK2, Janus-associated kinase 2; Ldlr, low-density lipo-
protein receptor; LPS, lipopolysaccharide; MCP1, monocyte chemoattractant protein 1; NET, neutrophil extracellular trap; NLRP3, NOD-, LRR-, and pyrin
domain-containing protein 3; PF-4, platelet factor 4; SHP2, Src homology phosphatase 2; STAT3, signal transducer and activator of transcription 3;
TET2, Tet methylcytosine dioxygenase 2; TNF-a, tumor necrosis factor-a; VAF, variant allele frequency; N/A, not applicable.
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tein 1 (MCP1 or CCL2), and TNF-a have been reported in
CHIP patients, supporting a complex or heterogeneous in-
flammatory response (Cook et al., 2019). Notably, IL-6 defi-
ciency reduces the risk of CHIP-associated CVD, indicating
a key role for IL-6 (Bick et al., 2020). The cell types respon-
sible for producing these other cytokines are not yet
known. Collectively, these studies suggest that inflamma-
tion andmacrophages play critical roles in CHIP-associated
CVD; however, multiple inflammatory pathways and he-
matopoietic cell typesmay promote pathogenesis (Table 1).
AdditionalHematopoietic LineagesMayContribute to
CHIP-Associated CVD
In addition to macrophages, many other hematopoietic
lineages participate in CVD. Consequently, they may be
altered by CHIP andmaymodify the pathogenesis and out-
comes of CHIP-associated CVD. For example, perivascular
mast cells release pro-inflammatory cytokines, such as IL-
6 and interferon-g, and facilitate atherosclerotic plaque
destabilization (Bot et al., 2007; Lagraauw et al., 2019;
Sun et al., 2007). Loss of Dnmt3a in mast cells increases
cytokine release, enhances degranulation capacity, and in-
creases sensitivity to stimuli (Leoni et al., 2017). Levels of
mast cells correlate with an increased risk of adverse cardio-296 Stem Cell Reports j Vol. 15 j 292–306 j August 11, 2020vascular (CV) events, supporting an important clinical role
for mast cells in CVD (Willems et al., 2013). Consequently,
CHIP-associated genesmay also promote the inflammatory
response in CVD via mast cells. CHIP-associated mutations
were recently associated with differential effects on platelet
number and risk for thrombosis and bleeding, and pro-in-
flammatory lymphoid lineages have been detected in
CHIP patients with CVD (Mas-Peiro et al., 2020; Veninga
et al., 2020). Furthermore, individuals exhibiting CH for
the JAK2V617F mutation have an increased occurrence of
thrombosis associated with neutrophil extracellular traps
(NETs), indicating another hematopoietic lineage that
can contribute to CHIP-associated CVD (Wolach et al.,
2018). In this context, this increased risk of thrombosis
does not appear to be associated with CV risk factors, infer-
ring that CHIP alone may increase the risk of CVD. Addi-
tional studies are needed to elucidate the functions of these
different hematopoietic cell types in CHIP-associated CVD.
Differences in the distribution and functions of hemato-
poietic lineagesmay influence themanifestation of inflam-
mation at different stages of pathogenesis and may have
important implications for disease heterogeneity and the
treatment of CHIP-associated CVD. For example, muta-
tions in TET2 may lead to an accumulation of pro-inflam-
matory macrophages, whereas mutations in JAK2 and
Figure 2. Different CHIP-Associated Mu-
tations May Have Differential Effects on
the Distinct Hematopoietic Lineages
That Contribute to CVD
(A) Many different hematopoietic lineages
contribute to CVD. In atherosclerosis, pro-
inflammatory macrophages (purple) accel-
erate plaque formation. Mast cells (blue)
and neutrophils (green) promote throm-
bosis via IL-6 and neutrophil extracellular
traps, respectively. B cells (brown) secrete
antibodies and cytokines. Polarized T cells
(orange) facilitate inflammation. All of
these cell types have the potential to carry
CHIP-associated mutations (yellow star)
and to alter CHIP-associated CVD.
(B) Different CHIP-associated mutations
may influence the cell types involved in and
the pathogenesis of CHIP-associated CVD at
different stages. Loss of TET2, JAK2, and
DNMT3A has been associated with macro-
phages, neutrophils, and mast cells and
T cells, respectively.
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neutrophils, mast cells, and T cells (Figure 2). These
changesmay influence the ability to resolve inflammation.
Single-cell RNA sequencing has identified functional sub-
types of these cell types, further complicating the potential
implications of CHIP-associated mutations (Winkels et al.,
2018). In addition, cell-type-specific functions of the
NLRP3 inflammasome have been reported in myocardial
infarction, providing an opportunity formultiple cell types
to modulate this pathway (Takahashi, 2019).
Different CHIP-associated genes differentially affect the
various hematopoietic lineages, biasing the distribution
of these lineages toward specific cell populations. For
example, inactivation of the Tet2 gene promotes a myeloidshift and can alter mast cell differentiation and prolifera-
tion (Montagner et al., 2016; Buscarlet et al., 2018). In
CHIP patients undergoing transcatheter aortic valve im-
plantation for degenerative aortic valve stenosis, DNMT3A
mutations were associated with pro-inflammatory T cells,
whereasTET2mutations correlatedwith pro-inflammatory
non-classical monocytes, suggesting that different muta-
tions may influence the hematopoietic lineages that can
contribute to CHIP-associated CVD (Mas-Peiro et al.,
2020). While both the T cells and monocytes were pro-in-
flammatory, it is not yet known if they promote inflamma-
tion via a common mechanism. CHIP-associated muta-
tions have been detected in lymphoid lineages; however,
the implications of lymphoid lineages for CHIP-associatedStem Cell Reports j Vol. 15 j 292–306 j August 11, 2020 297
Stem Cell Reports
ReviewCVD have not yet been explored (Boettcher et al., 2020;
Buscarlet et al., 2018). Significantly, the penetrance of
CHIP-associated mutations in different hematopoietic lin-
eages depends on the specific gene carrying the mutation.
In CHIP patients carrying single DNMT3A mutations,
41% of the peripheral mononuclear cells (PMNs) weremul-
tipotent, while 36% and 23%weremyeloid andmyelolym-
pho-B cells, respectively. The VAFs in the myelolympho-B
and multipotent lineages were 10% or greater, while the
VAF in the myeloid lineage was less than 10% (Buscarlet
et al., 2018). In contrast, CHIP patients bearing single
TET2mutations exhibited 54% of PMNs from the myeloid
lineage and 46% from the myelolympho-B lineage. The
VAFs were approximately 10% in both the myeloid and
myelolympho-B lineages (Buscarlet et al., 2018). In HSCT
donors with CHIP and their recipients, granulocytes,
monocytes, B cells, and T cells demonstrated mean VAFs
of 0.08, 0.083, 0.028, and 0.007, respectively (Boettcher
et al., 2020). These studies support the notion that different
CHIP-associated mutations may differentially affect the
distribution of the affected hematopoietic cell types and
their functions in CVD. These mutation-specific and
cell-type differences may have important implications
for the clinical presentations, prognoses, and latencies
of and the therapeutic development for CHIP-associated
CVD.
Epigenetic Regulators May Drive the Distributions of
Hematopoietic Lineages andMay Contribute to CHIP-
Associated CVD
As epigenetic regulators are frequently mutated in CHIP,
epigenetic modulationmay contribute to the pathogenesis
of CHIP-associated CVD (Jaiswal et al., 2017). Mutations in
and loss of CHIP-associated epigenetic regulators in HSPCs
differentially affect the resulting hematopoietic lineages,
supporting an important role for stem cells in the patho-
genesis of CHIP-associated diseases (Buscarlet et al.,
2018). Inactivation of Tet2 or Asxl1 in HSPCs leads to
moremyeloid phenotypes, whereas loss ofDnmt3a in these
cells causes bothmyeloid and lymphoid disease, indicating
that these epigenetic regulators can affect the availability of
hematopoietic lineages (Abdel-Wahab et al., 2013; Li et al.,
2011; Mayle et al., 2015). However, the effects of these
CHIP-associated genes on the distribution of hematopoiet-
ic lineages, disease severity, latency, and penetrance of
CHIP-associated CVD are not yet known.
In addition to skewing the differentiation of HPSCs,
epigenetic regulation may also influence the contributions
of mature hematopoietic cell types to CHIP-associated
CVD as epigenetic regulation contributes to atheroscle-
rosis, heart failure, and inflammation (Rizzacasa et al.,
2019). For example, differences in DNA methylation de-
tected in atherosclerotic and normal aortas may correlate298 Stem Cell Reports j Vol. 15 j 292–306 j August 11, 2020with disease progression, and loss of histone deacetylase
3 exacerbates atherosclerosis (Zampetaki et al., 2010; Va-
lencia-Morales Mdel et al., 2015). Exercise can modulate
epigenetic factors in a model of atherosclerosis, indicating
that epigenetic differences may alter the ability to respond
to environmental influences that affect CVD (Frodermann
et al., 2019). Many of these studies report epigenetic
changes in endothelial cells or vascular smooth muscle
cells; however, less is known about the effects of epigenetic
modification in hematopoietic lineages on CVD.
Many opportunities exist for epigenetic regulators to
alter the functions of mature hematopoietic lineages. For
example, TET2 regulates the expression of NLRP3 and IL-
1b (Fuster et al., 2017). Previously, our group demonstrated
that the long-noding RNAMorrbid is increased in Tet2-defi-
cient cells challengedwith lipopolysaccharide and that loss
of Morrbid ameliorates the inflammatory phenotype of
Tet2-deficient cells, broadening the impact of epigenetic
regulation in CH and suggesting that multiple epigenetic
regulators may be important in CH (Cai et al., 2018).
Notably, Dnmt3a is upregulated in response to altered
blood flow and can modulate the expression levels of
angiotensin-converting enzyme (ACE), which regulates
blood pressure, in endothelial cells in response to inflam-
mation (Figure 4) (Davies et al., 2014; Mudersbach et al.,
2019). Cardiac mast cells also secrete renin, an upstream
regulator of angiotensin, and the release of renin can
contribute to various manifestations of CVD (Mackins
et al., 2006; Reid et al., 2007). These observations suggest
a role for mast cells in blood pressure regulation and the
ability of CHIP-associated genes to influence blood pres-
sure. Notably, CHIP patients more frequently exhibit
hypertension; however, the mechanisms are not under-
stood (Dorsheimer et al., 2019). These epigenetic changes
maymodify the distributions and functions of the hemato-
poietic lineages that modulate CHIP-associated CVD.
These studies suggest that there are multiple possible
mechanisms by which epigenetic factors can affect CHIP-
associated CVD.
Inflammation and CVD Can Influence Hematopoiesis
While epigenetic regulationmay impact the hematopoietic
lineages contributing to CHIP-associated CVD, inflamma-
tion may also shape the distributions of these cell types
as cytokines play a critical role in regulating hematopoiesis
(Fuster et al., 2017). Associated with stresses, such as infec-
tion, inflammation mobilizes HSPCs and influences differ-
entiation patterns to bolster the immune system. For
example, the NLRP3 inflammasome, interferon-g, and
IL-1 promote the mobilization of HSPCs (de Bruin et al.,
2014; Lenkiewicz et al., 2019; Mantovani et al., 2019).
However, the timing of the inflammatory response may
be critically important as chronic inflammation is
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2019; Pietras et al., 2016). In addition, different cytokines
may exert differential effects depending on the context
and the other inflammatory mediators present, both of
which may be altered by CHIP (Mantovani et al., 2019).
We and others have shown that Tet2-deficient HSPCs
secrete cytokines and that inflammation promotes the
expansion of these HSPCs, suggesting that, in addition to
mature hematopoietic lineages, HSPCs carrying CHIP-asso-
ciated mutations may actively contribute to the inflamma-
tion observed in CHIP (Abegunde et al., 2018; Cai et al.,
2018). These findings are consistent with the observation
that transplantation of Tet2-deficient BM is sufficient to
cause CHIP-associated CVD (Wang et al., 2020).
In addition to promoting the expansion of clones car-
rying CHIP-associated mutations, inflammation can also
alter the BM microenvironment (Leimkuhler and
Schneider, 2019). Inflammation and the BMmicroenviron-
ment change with age, influencing the context in which
CHIP-associated inflammation occurs (Ho et al., 2019; Kov-
tonyuk et al., 2016). As loss of either Tet2 or Dnmt3a is
implicated in inflammation, HSPCs carrying CHIP-associ-
ated mutations and/or the presence of CHIP-associated
CVD may promote an inflammatory state that can alter
the BM microenvironment, leading to more permanent
changes in hematopoiesis and a propensity to promote
HSPC damage. It has been proposed that, in CVD, mature
hematopoietic cells and HSPCs create a reinforcing feedfor-
ward system in which the inflammation from one fuels the
other (Chavakis et al., 2019). This notionmay also apply in
CHIP. Elevated levels of cytokines and chemokines have
been detected in the serum of CHIP patients, indicating
that these patients exhibit systemic inflammation (Cook
et al., 2019). However, changes in the BM microenviron-
ment of patients with CHIP or CHIP-associated CVD have
not yet been investigated.
CVD can also increase hematopoietic activity, identi-
fying a means of communication between the CV and he-
matopoietic systems (Al-Sharea et al., 2019a, 2019b).
Ischemic stroke and atherosclerosis stimulate HSPCs (Cour-
ties et al., 2015; van der Valk et al., 2017). HSCTs have been
evaluated to treat infarction and ischemic damage as
HSPCs can home to injured heart tissues (Kavanagh and
Kalia, 2011; Vagnozzi et al., 2020). In addition, exercise al-
leviates CV inflammation by modulating hematopoiesis
(Frodermann et al., 2019). The existence of these effects im-
plies the possibility of a system inwhich the hematopoietic
and CV systems may reciprocally influence disease
progression in CHIP. Hypertension leads to unstable
atherosclerotic lesions due to stimulation of hematopoiesis
(Al-Sharea et al., 2019b). Remarkably, stress-induced
hypertension causes depletion of HSPCs and reduction of
osteoblasts and sinusoidal endothelial cells in the BMmicroenvironment, suggesting that hypertension may
also promote remodeling of the BM microenvironment
(Al-Sharea et al, 2019b). As DNMT3A can regulate ACE
expression, mutations in DNMT3A may lead to an eleva-
tion in blood pressure that modulates the BM microenvi-
ronment (Figure 4) (Mudersbach et al., 2019). It remains
to be seen if loss of DNMT3A function in hematopoietic
cells can dysregulate ACE expression. Importantly, as
CHIP is predominant in older individuals, CHIP-associated
diseases will also occur in an older CV system, which is
characterized by increased cardiac leukocytes, including
monocyte-derived cardiac macrophages, granulocytes,
and CD8+ Tcells (Swirski and Nahrendorf, 2018). These ag-
ing-associated changes in the CV system may also have
important implications for CHIP-associated CVD. Collec-
tively, these observations raise the possibility that CHIP-
associated mutations may trigger a cascade of events that
alters hematopoiesis and/or the BM microenvironment
via inflammation and cardiac physiology.
CHIP-Associated CVD and Hematological Malignancy
May Represent a Progression of the Same Disease
Process
The communication between the CV and hematopoietic
systems supports a potential interaction between these sys-
tems in CHIP-associated CVD. Increased reports of CVD in
patients with hematological malignancies further suggest
that these pathologies may coexist or represent a spectrum
of clinical presentations. For example, patients with acute
leukemia exhibit increased left ventricle masses and vol-
umes and decreased global longitudinal strain before
chemotherapy, demonstrating an inherent CV deficit in
patients with hematological malignancies (Assuncao
et al., 2017). In addition, patients with hematological ma-
lignancies can exhibit CVD and CV toxicities to chemo-
therapy, and these toxicities appear to increase with age,
suggesting that these patientsmay also bemore susceptible
to CV injury (Dickerson et al., 2019; Malato et al., 2010). It
is currently unclear if CHIP contributes to these pathol-
ogies; however, a more thorough understanding of the
role of CHIP in CVD may help identify patients who will
be more susceptible to the development of CVD and CV
toxicities. An increased incidence of thrombosis associated
with JAK2V617F mutations was observed in patients with
myeloproliferative neoplasms, demonstrating the possibil-
ity that cancer and CVD can coexist (Wolach et al., 2018).
Patients with myeloproliferative disease and increased
thrombotic events also have an increased risk of
secondary cancers (De Stefano et al., 2020). Together, these
studies support a potential link between CVD and onco-
genesis. However, while CHIP is associated with an
increased risk of both hematological malignancies and
CVD, it is not yet known if these pathologies occur in theStem Cell Reports j Vol. 15 j 292–306 j August 11, 2020 299
Figure 3. Potential Outcomes for the Evo-
lution of CHIP-Associated CVD and Hema-
tological Malignancy from HSPCs Carrying
CHIP-Associated Mutations
Mutant clones (red) can expand or be
maintained. As CHIP has been linked to both
CVD and hematological malignancy, expan-
sion of mutant clones may lead to CVD
alone, hematological malignancy alone, or a
combination of CVD and hematological ma-
lignancy. The acquisition of additional mu-
tations (green) is usually needed to promote
the evolution of CH to hematological ma-
lignancy and often requires an inciting
event (lightning bolt). It is not yet known if
CVD and hematological malignancy repre-
sent progression of the same disease pro-
cess or distinct events. However, the
inflammation from CHIP-associated CVD
may drive the acquisition of additional
mutations and the progression to hemato-
logical malignancy.
Stem Cell Reports
Reviewsame individuals, if they represent a spectrum of disease
progression, or if they are distinct events. Consequently,
there are several possible outcomes associated with CHIP
(Figure 3). Individuals may carry CHIP-associated muta-
tions, but the mutant clones maintain their size and
fail to contribute to pathology. If the mutant clones
expand, theymay lead to CVD, hematological malignancy,
or both. Longitudinal studies of CHIP patients are
needed to fully understand the progression of CHIP-associ-
ated diseases and the contributions of different clinical
presentations.
Commonalities exist between the pathogenesis of CVD
and cancer, including cell proliferation, apoptosis, inflam-
mation, leukocyte infiltration, and remodeling of the extra-
cellularmatrix (Libby andKobold, 2019; Tapia-Vieyra et al.,
2017). These similarities and the ability of the CV and he-
matological systems to communicate may allow these con-
ditions to coexist and evolve simultaneously. In particular,
inflammation may serve as a unifying driver of pathogen-
esis for CVD and hematological malignancy as it is an
important factor in both of these pathologies. TNF-a pro-
motes survival of HSPCs and myeloid regeneration, and
IL-6 facilitates the development of chronic myeloid leuke-
mia, indicating that inflammation can promote leukemo-
genesis (Reynaud et al., 2011; Yamashita and Passegue,
2019). Additional mutations are often required for the
development of leukemia and are obtained during clonal
evolution of HSPCs (Sanden et al., 2020). In preleukemic300 Stem Cell Reports j Vol. 15 j 292–306 j August 11, 2020scenarios, inflammation can promote genotoxic stress
and disease progression, suggesting that inflammation
may create an environment in which HSPCs carrying
CHIP-associated mutations can acquire additional muta-
tions and facilitate leukemogenesis (Zambetti et al., 2016).
A potential explanation for the coexistence of CHIP-asso-
ciated CVD and hematological malignancy is that raised
blood pressure from increased expression of ACE or renin
or cytokines fromHSPCs or mature hematopoietic lineages
may act as selective pressures that facilitate the remodeling
of the BMmicroenvironment (Figure 4). Interferon-g from
the BM can reduce the size of atherosclerotic plaques in
Ldlr-deficient mice, indicating that signals from the BM
can modulate CVD (Niwa et al., 2004). In addition, the
vascular niche, a component of the BM microenviron-
ment, plays an important role in hematopoiesis and leuke-
mogenesis; however, it is not known if CHIP-associated
CVD alters the vascular niche (Duarte et al., 2018; Sasine
et al., 2017). If so, changes in the vascular niche due to
CHIP-associated CVD may link CVD and hematological
malignancy in CHIP. These changes in the BM microenvi-
ronment may create a biological context conducive to
leukemogenesis and genotoxic stress (Figure 4). It is also
compelling to consider the ways in which changes in
clonal dynamics may modify the CVD presentation.
Further studies are needed to investigate these interactions
and the potential co-occurrence of CHIP-associated CVD
and hematological malignancies. Collectively, these
Figure 4. Model for Altered Hematopoie-
sis and the Development of Hematologi-
cal Malignancy in Response to CHIP-Asso-
ciated CVD
Loss of CHIP-associated genes is associated
with an increased release of cytokines from
HSPCs and mature hematopoietic lineages.
These cytokines may promote expansion of
the mutant clones and CVD. Increased
inflammation and blood pressure are asso-
ciated with CVD. Both of these changes can
alter the BM microenvironment, which
contributes to hematopoiesis. These
stresses on the BM microenvironment may
aberrantly alter hematopoiesis to promote
hematological malignancy and may create
genotoxic stress that facilitates the acqui-
sition of additional mutations. MC, mesen-
chymal cell; EC, endothelial cell.
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between the CV and hematopoietic systems and under-
score the importance of studying the consequences of
this relationship for CHIP.
CHIP Has Implications for the Treatment of CVD
Current studies indicate anti-inflammatory agents, such as
inhibitors of IL-1b and the NLRP3 inflammasome, as poten-
tial treatments for CHIP-associated CVD (Fuster et al., 2017).
As the inflammatory response can manifest as a complex
and dynamic cascade, the timing of treatment with anti-in-
flammatory therapeutics may be critical. Different cyto-
kines, inflammatory pathways, and hematopoietic lineages
may play important roles at different times during the in-
flammatory response and during CVD and may represent
potential therapeutic targets. Presently, these anti-inflam-
matory agents appear to target mature hematopoietic line-ages, but it is intriguing to consider whether HSPCs bearing
CHIP-associated mutations could be directly targeted. Our
group has shown that inhibition of inflammation can
impede the expansion of HSPCs bearing CHIP-associated
mutations, suggesting that inflammation also contributes
to the pathogenic functions of mutant HSPCs in CHIP
(Cai et al., 2018). It is not yet known if blocking the expan-
sion of these mutant HSPCs can ameliorate CHIP-associated
CVD. Inhibiting the differentiation and function of specific
hematopoietic lineages and targeting aberrant proteins en-
coded by genes bearing CHIP-associated mutations may
also be valuable approaches. For example, the JAK2 inhibitor
ruxolitinib effectively inhibits NET formation and decreases
thrombosis in mice (Wolach et al., 2018), indicating that
directly targeting the mutant proteins associated with
CHIP may abrogate the altered hematopoietic cell types
contributing to CVD.Stem Cell Reports j Vol. 15 j 292–306 j August 11, 2020 301
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CHIP is currently unclear (Libby et al., 2019b). If anti-in-
flammatory agents can prevent CHIP-associated CVD,
then screening for CHIP-associated mutations could
identify patients who may benefit from prophylactic
anti-inflammatory treatment. However, patients present-
ing with cardiac symptoms likely already have active dis-
ease, emphasizing the importance of identifying
therapies that can treat existing disease. An important
question in understanding the clinical relevance of
CHIP-associated CVD is whether it differs from tradi-
tional CVD. Screening for CHIP-associated CVD would
be most advantageous if it could be used to guide treat-
ment decisions. While current studies indicate that
inflammation may be a key mechanism by which CHIP
contributes to CVD, inflammation also plays an impor-
tant role in CVD in general. For example, canakinumab,
an antibody against IL-1b, is also efficacious in tradi-
tional CVD (Ridker et al., 2017). The observation that
transplantation of Tet2-deficient BM can induce CVD
suggests that CHIP-associated mutations may be suffi-
cient to cause CVD in the absence of additional cardiac
risk factors (Wang et al., 2020). Larger epidemiological
studies are needed to more fully understand the clinical
consequences of CHIP-associated CVD, the ways in
which it differs from other types of CVD, and the mech-
anisms by which it interacts with other CVD risk factors.
This knowledge will promote the development of
therapeutics that can specifically target this patient
population.
The screening of specific CHIP-associated mutations
may also have significant implications for the clinical
manifestation, disease progression, and cell types
involved. Understanding the effects of specific mutations
may be able to promote a precision medicine approach
to treating CHIP-associated CVD in the future. However,
as the presence of different comorbidities can also influ-
ence CH, the manifestation of CHIP-associated CVD may
be affected by these comorbidities (Dragoljevic et al.,
2018). This possibility may complicate the utility of ge-
netic screening for predicting prognosis and guiding
treatment. In considering potential therapies for CHIP-
associated CVD, it is important to also consider the abil-
ity of these therapies to modulate the leukemic potential
of preleukemic HSPCs carrying CHIP-associated muta-
tions. Treatment with anti-inflammatory agents may
alter the distribution of cytokines influencing hemato-
poiesis, potentially modifying the resulting hematopoi-
etic lineages and promoting leukomogenesis. Collec-
tively, these studies indicate the complexities of
treating CHIP-associated CVD and underscore the impor-
tance of future studies to better understand its pathogen-
esis and to facilitate the development of novel therapies.302 Stem Cell Reports j Vol. 15 j 292–306 j August 11, 2020Conclusions
CHIP is a common novel risk factor for both CVD and he-
matological malignancy. Many unanswered questions
remain regarding its underlying mechanisms. Inflamma-
tion may play a critical role in the pathogenesis of CHIP-
associated CVD; however, additional studies are needed
to fully understand its complexity and impact. Further-
more, it is not yet known if inflammation is a common
mechanism for CHIP-associated mutations. As many
different hematopoietic lineages contribute to CVD, it is
likely that CHIP-associated mutations in HSPCs are trans-
mitted to multiple hematopoietic cell types and that these
different cell types can influence clinical presentation and
disease progression. These differences may be affected by
specific CHIP-associated mutations and may have impor-
tant implications for disease heterogeneity and treatment.
Inflammation may also serve as a key link between CVD
and hematological malignancy. The relationship between
CVD and cancer development in CHIP patients remains
unexplored but represents a fascinating new area in car-
dio-oncology, highlighting compelling links between the
CV and hematological systems. Further elucidation of the
disease characteristics unique to CHIP-associated CVD
will facilitate the discovery of new therapies and improve
the clinical care of CHIP patients.
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